Scilex Holding (SCLX) Return on Capital Employed (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Return on Capital Employed of 203.13% for Q1 2026, up 15475.0% year-over-year from N/an in Q1 2025, and down 4.18% quarter-over-quarter from 211.99% in Q4 2025.
Scilex Holding (SCLX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Scilex Holding's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 203.13% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 15475.0% year-over-year to 203.13%; the TTM figure through Mar 2026 stood at 203.13% (up 15475.0% YoY), while the FY2025 annual figure was 135.86%, up 8454.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 203.13%, down from 211.99% in the prior quarter.
- The five-year high for Return on Capital Employed was 211.99% in Q4 2025, with the low at 2940.51% in Q2 2023.
- The 5-year median for Return on Capital Employed is 48.38% (2025), against an average of 145.26%.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 290096 bps in 2023, then jumped 299906 bps in 2024.
- Scilex Holding's Return on Capital Employed stood at 103.02% in 2022, then jumped by 164 bps to 66.12% in 2023, then slipped by 23 bps to 51.18% in 2024, then soared by 314 bps to 211.99% in 2025, then declined by 4 bps to 203.13% in 2026.
- Business Quant data shows SCLX's Return on Capital Employed at 203.13% in Q1 2026, 211.99% in Q4 2025, and 146.98% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 137.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 203.13% |
| Dec 31, 2025 | 211.99% |
| Sep 30, 2025 | 146.98% |
| Jun 30, 2025 | 43.06% |
| Mar 31, 2025 | 48.38% |
| Dec 31, 2024 | 51.18% |
| Sep 30, 2024 | 40.97% |
| Jun 30, 2024 | 58.55% |
| Mar 31, 2024 | 63.55% |
| Dec 31, 2023 | 66.12% |
| Sep 30, 2023 | 85.41% |
| Jun 30, 2023 | -2,940.51% |
| Mar 31, 2023 | -310.33% |
| Dec 31, 2022 | -103.02% |
| Sep 30, 2022 | -54.61% |
| Jun 30, 2022 | -39.55% |
| Mar 31, 2022 | -40.65% |
| Dec 31, 2021 | 59.11% |
| Sep 30, 2021 | -0.45% |
| Jun 30, 2021 | -0.25% |